Back to today’s briefing

Story perspectives

FDA Approves Zynyz for Anal Cancer Amid Safety Concerns

6/13/2025

24 2

Summary

Story summary

In a significant breakthrough, the FDA has greenlit Incyte's Zynyz for treating advanced anal cancer, offering hope to patients. Meanwhile, GLP-1 receptor agonists, such as semaglutide, are under the microscope for possible connections to severe eye diseases, sparking a heated discussion about their overall safety and potential benefits in reducing age-related eye conditions.

1 of 1

Story summary

In a significant breakthrough, the FDA has greenlit Incyte's Zynyz for treating advanced anal cancer, offering hope to patients. Meanwhile, GLP-1 receptor agonists, such as semaglutide, are under the microscope for possible connections to severe eye diseases, sparking a heated discussion about their overall safety and potential benefits in reducing age-related eye conditions.